首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   310140篇
  免费   28730篇
  国内免费   21719篇
耳鼻咽喉   3078篇
儿科学   3619篇
妇产科学   4917篇
基础医学   37254篇
口腔科学   5468篇
临床医学   40055篇
内科学   45655篇
皮肤病学   2975篇
神经病学   17823篇
特种医学   12012篇
外国民族医学   213篇
外科学   32776篇
综合类   49666篇
一般理论   20篇
预防医学   18985篇
眼科学   9493篇
药学   32358篇
  234篇
中国医学   17554篇
肿瘤学   26434篇
  2024年   191篇
  2023年   4510篇
  2022年   6924篇
  2021年   12603篇
  2020年   12300篇
  2019年   14208篇
  2018年   8997篇
  2017年   9674篇
  2016年   7948篇
  2015年   13382篇
  2014年   17442篇
  2013年   14904篇
  2012年   22172篇
  2011年   25088篇
  2010年   15862篇
  2009年   12220篇
  2008年   16989篇
  2007年   17005篇
  2006年   17031篇
  2005年   16760篇
  2004年   10649篇
  2003年   9749篇
  2002年   8411篇
  2001年   7433篇
  2000年   8248篇
  1999年   8947篇
  1998年   5345篇
  1997年   5402篇
  1996年   4238篇
  1995年   3925篇
  1994年   3220篇
  1993年   2102篇
  1992年   2821篇
  1991年   2413篇
  1990年   2110篇
  1989年   1855篇
  1988年   1565篇
  1987年   1302篇
  1986年   1079篇
  1985年   911篇
  1984年   520篇
  1983年   371篇
  1982年   237篇
  1981年   226篇
  1980年   186篇
  1979年   222篇
  1978年   82篇
  1977年   90篇
  1974年   101篇
  1973年   83篇
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
2.
3.
4.
5.
6.
7.
8.
9.
In clear cell renal cell carcinoma (ccRCC), glycolysis is enhanced mainly because of the increased expression of key enzymes in glycolysis. Hence, the discovery of new molecular biomarkers for glycolysis may help guide and establish a precise system of diagnosis and treatment for ccRCC. Expression profiles of 1079 tumor samples of ccRCC patients (including 311 patients treated with everolimus or nivolumab) were downloaded from public databases. Proteomic profiles of 232 ccRCC samples were obtained from Fudan University Shanghai Cancer Center (FUSCC). Biological changes, tumor microenvironment and prognostic differences were explored between samples with various glycolysis characteristics. There were significant differences in CD8+ effector T cells, epithelial-to-mesenchymal transition and pan-fibroblast TGFb between the Low and High glyScore groups. The tumor mutation burden of the Low glyScore group was lower than that of the High glyScore group. And higher glyScore was significantly associated with worse overall survival (OS) in 768 ccRCC patients (P < .0001). External validation in FUSCC cohort also indicated that glyScore was of strong ability for predicting OS (P < .05). GlyScore may serve as a biomarker for predicting everolimus response in ccRCC patients due to its significant associations with progression-free survival (PFS). And glyScore may also predict overall survival in patients treated with nivolumab. We calculated the glyScore in ccRCC and the defined glyScore was of strong ability for predicting OS. In addition, glyScore may also serve as a biomarker for predicting PFS in patients treated with everolimus and could predict OS in patients treated with nivolumab.  相似文献   
10.
The purpose of this study was to provide an evidence base for colorectal cancer research activity that might influence policy, mainly at the national level. Improvements in healthcare delivery have lengthened life expectancy, but within a situation of increased cancer incidence. The disease burden of CRC has risen significantly, particularly in Africa, Asia and Latin America. Research is key to its control and reduction, but few studies have delineated the volume and funding of global research on CRC. We identified research papers in the Web of Science (WoS) from 2007 to 2021, and determined the contributions of the leading countries, the research domains studied, and their sources of funding. We identified 62 716 papers, representing 5.7% of all cancer papers. This percentage was somewhat disproportionate to the disease burden (7.7% in 2015), especially in Eastern Europe. International collaboration increased over the time period in almost all countries except in China. Genetics, surgery and prognosis were the leading research domains. However, research on palliative care and quality-of-life in CRC was lacking. In Western Europe, the main funding source was the charity sector, particularly in the UK, but in most other countries government played the leading role, especially in China and the USA. There was little support from industry. Several Asian countries provided minimal contestable funding, which may have reduced the impact of their CRC research. Certain countries must perform more CRC research overall, especially in domains such as screening, palliative care and quality-of-life. The private-non-profit sector should be an alternative source of support.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号